ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

Core Insights - ImageneBio, Inc. has appointed Dr. Ben Porter-Brown as Chief Medical Officer to lead the clinical organization and the Phase 2b ADAPTIVE trial in atopic dermatitis [1][2][3] Company Overview - ImageneBio is a clinical-stage biotechnology company focused on developing therapeutics for immunological, autoimmune, and inflammatory diseases, with a specific emphasis on the anti-OX40 monoclonal antibody, IMG-007 [5] Leadership Appointment - Dr. Porter-Brown brings over 20 years of experience in autoimmune and inflammatory diseases, particularly in the OX40-OX40L inhibition field, and has previously held significant roles at MoonLake Immunotherapeutics and Kymab [3][4] - His expertise is expected to enhance the execution of the Phase 2b ADAPTIVE trial and the overall clinical strategy of Imagene [2][4] Clinical Development Plans - The Phase 2b ADAPTIVE trial will expand its footprint with planned international sites in the UK and Europe, aiming to address the treatment gap for patients with moderate-to-severe atopic dermatitis [1][4] - IMG-007 is positioned as a novel treatment option that may offer disease-modifying potential, differing from currently approved therapies [4] Financial Incentives - As part of his appointment, Dr. Porter-Brown will receive an inducement award of 137,000 shares of common stock, contingent upon his employment with a subsidiary in the UK [4]